Cargando…

Favipiravir and the Need for Early Ambulatory Treatment of COVID-19

Detalles Bibliográficos
Autor principal:	Korman, Tony M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society for Microbiology 2021
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8092553/ https://www.ncbi.nlm.nih.gov/pubmed/33288636 http://dx.doi.org/10.1128/AAC.02489-20

Ejemplares similares

Favipiravir and the Need for Early Ambulatory Treatment of SARS-CoV-2 Infection (COVID-19)
por: McCullough, Peter A.
Publicado: (2020)

Clinical efficacy and safety of favipiravir in the treatment of COVID-19 patients
por: Chen, Ping-Jen, et al.
Publicado: (2021)

Hematological Malignancy Patients, COVID-19, and Favipiravir
por: Mungmunpuntipantip, Rujittika, et al.
Publicado: (2021)

Favipiravir Experience in Covid-19 Positive Myasthenia Gravis Patients
por: Yevgi, Recep, et al.
Publicado: (2021)

ICU admission and favipiravir
por: Mungmunpuntipantip, Rujittika, et al.
Publicado: (2021)

Intravenous Immunoglobulin and Favipiravir treatment for A Kidney Transplant Patient with Severe Covid-19 Pneumonia
por: Tatar, Erhan, et al.
Publicado: (2020)

An unusual case of bluish discoloration of the cornea after favipiravir therapy for COVID-19
por: Raiturcar, Tanvi P, et al.
Publicado: (2021)

Re: Efficacy of favipiravir in adults with mild COVID-19 by Bosaeed et al.
por: Mori, Nobuaki
Publicado: (2022)

Early Outpatient Treatment of SARS-CoV-2 (COVID-19): A Comment
por: Korman, Tony M., et al.
Publicado: (2021)

Adverse events associated with nafamostat mesylate and favipiravir treatment in COVID-19 patients
por: Hifumi, Toru, et al.
Publicado: (2020)

Use of Favipiravir in Lactating Mother With COVID-19
por: Karabayır, Nalan, et al.
Publicado: (2021)

Favipiravir-induced Liver Injury in Patients with Coronavirus Disease 2019
por: Kumar, Pramod, et al.
Publicado: (2021)

Rational Defensive Medicine: Putting an End to the Nationwide Favipiravir Debate
por: Öncel, Selim
Publicado: (2022)

Effect of favipiravir and an anti-inflammatory strategy for COVID-19
por: Yamamura, Hitoshi, et al.
Publicado: (2020)

Role of favipiravir in the treatment of COVID-19
por: Joshi, Shashank, et al.
Publicado: (2021)

COVID-19 thromboembolism is reduced in ambulatory, but not hospitalized patients, following COVID-19 vaccination
por: Stevens, Hannah, et al.
Publicado: (2023)

Trends in ambulatory cardiology consultations for suspected myocarditis after COVID-19 vaccination
por: Eggebrecht, Holger, et al.
Publicado: (2021)

When To Retest: an Examination of Repeat COVID-19 PCR Patterns in an Ambulatory Population
por: Greene, Dina N., et al.
Publicado: (2020)

Serum calprotectin is not an independent predictor of severe COVID-19 in ambulatory adult patients
por: Mentzer, Alexander J, et al.
Publicado: (2022)

Early favipiravir treatment was associated with early defervescence in non-severe COVID-19 patients
por: Fujii, Satoshi, et al.
Publicado: (2021)

Nafamostat mesylate treatment in combination with favipiravir for patients critically ill with Covid-19: a case series
por: Doi, Kent, et al.
Publicado: (2020)

Effectiveness of Early Favipiravir Therapy in Hospitalised COVID-19 Patients
por: Tawfik, Abdulrahman, et al.
Publicado: (2022)

Ambulatory Care in IR
por: Alderson, Jack, et al.
Publicado: (2022)

Physicians' Opinions of COVID-19 Ambulatory Care Constraints: A Survey of Sickle Cell Clinicians
por: Kenney, Martha O., et al.
Publicado: (2021)

Consideration Needed for early Anticoagulation Following Intravenous tPA in Patients with COVID-19
por: Jimenez, Angelo, et al.
Publicado: (2021)

Regarding the Article: A Multimodal Strategy to Reduce the Risk of Hospitalization/death in Ambulatory Patients with COVID-19
por: LEÓN-ROSALES, SAMUEL PONCE DE, et al.
Publicado: (2022)

The Anti-Influenza Virus Drug Favipiravir Has Little Effect on Replication of SARS-CoV-2 in Cultured Cells
por: Tomita, Yuriko, et al.
Publicado: (2021)

Response to: Regarding the Article: A Multimodal Strategy to Reduce the Risk of Hospitalization/death in Ambulatory Patients with COVID-19
por: BONILLA, CÉSAR RAÚL GONZALEZ
Publicado: (2022)

Response to the Letter to the Editor: Consideration Needed for Early Anticoagulation Following Intravenous tPA in Patients with COVID-19
por: Carneiro, Thiago, et al.
Publicado: (2021)

Efficacy and Safety of New and Emerging Drugs for COVID-19: Favipiravir and Dexamethasone
por: Sood, Shivani, et al.
Publicado: (2021)

Understanding the pharmacokinetics of Favipiravir: Implications for treatment of influenza and COVID-19
por: Ison, Michael G., et al.
Publicado: (2021)

Regional trends in the use of steroids and favipiravir for COVID-19 treatment
por: Asai, Yusuke, et al.
Publicado: (2023)

An economical and practical procedure of favipiravir synthesis for the treatment of Covid-19
por: Karatas, Hacer, et al.
Publicado: (2022)

Reduction in ambulatory visits for acute, uncomplicated bronchitis: an unintended but welcome result of the coronavirus disease 2019 (COVID-19) pandemic
por: Dilworth, Thomas J., et al.
Publicado: (2020)

Prevention of mucormycosis in COVID-19 – the need of the hour
por: Ish, Pranav, et al.
Publicado: (2021)

Adolescent COVID-19 vaccination: Need of the hour
por: Rajeshwari, Swetha, et al.
Publicado: (2022)

Letter to the editor on “Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label, multicenter, phase 3 clinical trial” by Udwadia et al
por: Medisetty, Mahender Kumar, et al.
Publicado: (2021)

Favipiravir in early symptomatic COVID-19, a randomised placebo-controlled trial
por: McMahon, James H., et al.
Publicado: (2022)

Diligence needed on treatment of primary multidrug-resistant pulmonary tuberculosis with concomitant COVID-19 infection
por: Thangaraju, Pugazhenthan, et al.
Publicado: (2022)

Favipiravir for COVID-19 in a Patient on Hemodialysis
por: Hirai, Daisuke, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_4q38sirlhf3usv9ucpj165sjip